In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Lyell Immunopharma Inc (NASDAQ: LYEL) closed at $2.23 in the last session, down -4.29% from day before closing price of $2.33. In other words, the price has decreased by -$4.29 from its previous closing price. On the day, 1.08 million shares were traded. LYEL stock price reached its highest trading level at $2.38 during the session, while it also had its lowest trading level at $2.15.
Ratios:
We take a closer look at LYEL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 16.07 and its Current Ratio is at 16.07. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on August 28, 2023, Downgraded its rating to Neutral and sets its target price to $5 from $15 previously.
On November 14, 2022, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $15 to $7.
Goldman Downgraded its Buy to Neutral on November 11, 2022, whereas the target price for the stock was revised from $13 to $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 15 ’23 when Klausner Richard sold 58,020 shares for $2.28 per share. The transaction valued at 132,286 led to the insider holds 930,880 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 566634112 and an Enterprise Value of 83578776. For the stock, the TTM Price-to-Sale (P/S) ratio is 4358.79 while its Price-to-Book (P/B) ratio in mrq is 0.86. Its current Enterprise Value per Revenue stands at 642.914 whereas that against EBITDA is -0.371.
Stock Price History:
Over the past 52 weeks, LYEL has reached a high of $3.97, while it has fallen to a 52-week low of $1.32. The 50-Day Moving Average of the stock is -1.40%, while the 200-Day Moving Average is calculated to be 5.36%.
Shares Statistics:
According to the various share statistics, LYEL traded on average about 929.07K shares per day over the past 3-months and 1291240 shares per day over the past 10 days. A total of 253.96M shares are outstanding, with a floating share count of 117.74M. Insiders hold about 53.66% of the company’s shares, while institutions hold 27.94% stake in the company. Shares short for LYEL as of 1711584000 were 18103897 with a Short Ratio of 19.49, compared to 1709164800 on 10953779. Therefore, it implies a Short% of Shares Outstanding of 18103897 and a Short% of Float of 10.15.
Earnings Estimates
Currently, Lyell Immunopharma, Inc. analysts are dedicated to thoroughly evaluating and rating the performance of Lyell Immunopharma Inc (LYEL) in the stock market.
